$VKTX (Viking Therapeutics, Inc.) — investor discussion on X

Five-factor rating: Sell (sector percentile 0.8%)

Graded daily on value F, growth D, profitability D-, momentum D-, revisions F. Sector-relative, identical for every user.

Recent discussion events

[bullish] Investors compare VK2735 favorably to Lilly's tirzepatide, citing superior weight loss potential and cheap valuation amid obesity drug discussions. (5 posts)

Most active credible voices on $VKTX

@pharmdca (Pharmdca) — 211 mentions · 105.3K followers
@semodough (dough) — 169 mentions · 44.6K followers
@acinvestorblog (Antonio Costa) — 78 mentions · 220.6K followers

Recent headlines featuring $VKTX

2026-09-27: Viking’s maintenance data keeps VK2735 in focus as analysts highlight 97% weight-loss retention
2026-09-24: Meta’s Muse reaches about 700,000 DAUs as shares jump over 30% in September
2026-09-23: Nasdaq-100 closes at record as SpaceX weight doubles to 2.82%
2026-09-22: Viking VK2735 maintenance data lifts shares premarket

Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $VKTX are available with SpikePanel Pro.

Stock Ratings · Today Headlines · SpikePanel

For richer charts and full features, open SpikePanel on desktop.

$VKTXViking Therapeutics, Inc. · Biotechnology · $3.7B

$28.67

0.0%

Event thread

Key events, in time order

13 items

2026-10-21 → 10-29EarningsBear
Viking Q3 Loss Widens, VK2735 Maintenance Data Met but Stock Fell
Q3 loss beat estimates on rising clinical costs; VK2735 maintenance study met criteria but failed to excite market
D1 -1.2% · +5d -3.9%
3 waves of this story
- 2026-10-21 Company announcement confirms earnings date and conference call, offering a key catalyst for investors
- 2026-10-29 Q3 update confirms VANQUISH Ph3 progress, oral SUNRISE initiation, positive maintenance dosing data
- 2026-10-29 Q3 loss beat estimates on rising clinical costs; VK2735 maintenance study met criteria but failed to excite market
2026-10-298-K filing
8-K: Item 2.02, Item 9.01
D1 +5.9% · +5d -4.0%

11 earlier events

2026-10-28Earnings
Earnings report
皮下VK2735的VANQUISH-1和VANQUISH-2两项III期研究已全部完成入组，预计首批患者将于2027年初进入扩展期。
D1 +1.9% · +5d +10.3%
2026-10-15Capital
Rex Shares Launches Peptide ETF; VKTX Among Top 10 Holdings
VKTX included at 3.84% weight, boosting institutional exposure
D1 +7.5% · +5d -5.6%
2026-10-02 → 10-09Capital
VKTX Rebounds 2.88% to $28.53 After Offering
Stock stabilizes post-offering as market digests dilution
D1 -1.9% · +5d -4.8%
2 waves of this story
- 2026-10-02 Dilution cuts EPS ~7.2%; earnings yield per dollar 14.4% lower
- 2026-10-09 Stock stabilizes post-offering as market digests dilution
2026-09-29 → 10-08Capital
Viking Appoints VP of Market Access, Bolsters Commercialization
New VP led U.S. market access strategy, preparing for product launch
D1 -3.7% · +5d -10.8%
3 waves of this story
- 2026-09-29 Company confirms closing, cash near $1B, funding pipeline
- 2026-09-30 High short interest post-financing, JP Morgan notes speculation of rejecting offers below $200, affecting sentiment
- 2026-10-08 New VP led U.S. market access strategy, preparing for product launch
2026-09-298-K filing
8-K: Item 1.01, Item 2.03, Item 9.01
D1 -3.7% · +5d -10.8%
2026-09-228-K filing
8-K: Item 8.01, Item 9.01
D1 +35.7% · +5d -22.1%
2026-08-08CapitalBull
Dimensional Fund Advisors Raises VKTX Stake by 18%
Institutional investor boosted stake 18% in Q1, reflecting positioning shift
D1 +0.5% · +5d -2.4%
2026-07-17 → 08-03RegulationBear
VKTX Faces Shareholder Probe, Q2 Earnings Loom
Analysts Seedhouse and pharmdca both cite VK2735 Phase 3 readout as key near-term catalyst, suggesting efficacy may be favorable vs. tirzepatide or retatrutide
D1 +2.0% · +5d -6.2%
3 waves of this story
- 2026-07-17 Law firm probes fiduciaries; Q2 report hinges on VK2735 updates
- 2026-07-26 Q2 call set for July 29; key items include Ph1 maintenance readout and Ph3 oral program initiation
- 2026-08-03 Analysts Seedhouse and pharmdca both cite VK2735 Phase 3 readout as key near-term catalyst, suggesting efficacy may be favorable vs. tirzepatide or retatrutide
2026-07-30Earnings
VKTX Reports Q2 Results, Phase 3 VK2735 Trials Fully Enrolled
Q2 loss narrower than expected, VK2735 Phase III advancing; Canaccord raises PT to $114, mixed shelf filed.
D1 -1.0% · +5d +0.6%
2 waves of this story
- 2026-07-30 Wider loss reported, but Phase 3 subcutaneous VK2735 fully enrolled; oral Phase 3 expected 4Q26
- 2026-07-30 Q2 loss narrower than expected, VK2735 Phase III advancing; Canaccord raises PT to $114, mixed shelf filed.
2026-07-298-K filing
8-K: Item 2.02, Item 9.01
D1 -1.3% · +5d +0.2%
2026-07-29Earnings
Earnings report
D1 -1.3% · +5d +0.2%

①

Bull vs bear

by direction · sourced

Bull signals0

None yet

Bear signals0

None yet

Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice

⑩

Discussion

be the first

Be civil · your views are your own

No comments yet.

Facts and opinions separated · All items sourced · Not investment advice

Event thread

Key events, in time order

13 items

2026-10-21 → 10-29EarningsBear
Viking Q3 Loss Widens, VK2735 Maintenance Data Met but Stock Fell
Q3 loss beat estimates on rising clinical costs; VK2735 maintenance study met criteria but failed to excite market
D1 -1.2% · +5d -3.9%
3 waves of this story
- 2026-10-21 Company announcement confirms earnings date and conference call, offering a key catalyst for investors
- 2026-10-29 Q3 update confirms VANQUISH Ph3 progress, oral SUNRISE initiation, positive maintenance dosing data
- 2026-10-29 Q3 loss beat estimates on rising clinical costs; VK2735 maintenance study met criteria but failed to excite market
2026-10-298-K filing
8-K: Item 2.02, Item 9.01
D1 +5.9% · +5d -4.0%
2026-10-28Earnings
Earnings report
皮下VK2735的VANQUISH-1和VANQUISH-2两项III期研究已全部完成入组，预计首批患者将于2027年初进入扩展期。
D1 +1.9% · +5d +10.3%
2026-10-15Capital
Rex Shares Launches Peptide ETF; VKTX Among Top 10 Holdings
VKTX included at 3.84% weight, boosting institutional exposure
D1 +7.5% · +5d -5.6%
2026-10-02 → 10-09Capital
VKTX Rebounds 2.88% to $28.53 After Offering
Stock stabilizes post-offering as market digests dilution
D1 -1.9% · +5d -4.8%
2 waves of this story
- 2026-10-02 Dilution cuts EPS ~7.2%; earnings yield per dollar 14.4% lower
- 2026-10-09 Stock stabilizes post-offering as market digests dilution

8 earlier events

2026-09-29 → 10-08Capital
Viking Appoints VP of Market Access, Bolsters Commercialization
New VP led U.S. market access strategy, preparing for product launch
D1 -3.7% · +5d -10.8%
3 waves of this story
- 2026-09-29 Company confirms closing, cash near $1B, funding pipeline
- 2026-09-30 High short interest post-financing, JP Morgan notes speculation of rejecting offers below $200, affecting sentiment
- 2026-10-08 New VP led U.S. market access strategy, preparing for product launch
2026-09-298-K filing
8-K: Item 1.01, Item 2.03, Item 9.01
D1 -3.7% · +5d -10.8%
2026-09-228-K filing
8-K: Item 8.01, Item 9.01
D1 +35.7% · +5d -22.1%
2026-08-08CapitalBull
Dimensional Fund Advisors Raises VKTX Stake by 18%
Institutional investor boosted stake 18% in Q1, reflecting positioning shift
D1 +0.5% · +5d -2.4%
2026-07-17 → 08-03RegulationBear
VKTX Faces Shareholder Probe, Q2 Earnings Loom
Analysts Seedhouse and pharmdca both cite VK2735 Phase 3 readout as key near-term catalyst, suggesting efficacy may be favorable vs. tirzepatide or retatrutide
D1 +2.0% · +5d -6.2%
3 waves of this story
- 2026-07-17 Law firm probes fiduciaries; Q2 report hinges on VK2735 updates
- 2026-07-26 Q2 call set for July 29; key items include Ph1 maintenance readout and Ph3 oral program initiation
- 2026-08-03 Analysts Seedhouse and pharmdca both cite VK2735 Phase 3 readout as key near-term catalyst, suggesting efficacy may be favorable vs. tirzepatide or retatrutide
2026-07-30Earnings
VKTX Reports Q2 Results, Phase 3 VK2735 Trials Fully Enrolled
Q2 loss narrower than expected, VK2735 Phase III advancing; Canaccord raises PT to $114, mixed shelf filed.
D1 -1.0% · +5d +0.6%
2 waves of this story
- 2026-07-30 Wider loss reported, but Phase 3 subcutaneous VK2735 fully enrolled; oral Phase 3 expected 4Q26
- 2026-07-30 Q2 loss narrower than expected, VK2735 Phase III advancing; Canaccord raises PT to $114, mixed shelf filed.
2026-07-298-K filing
8-K: Item 2.02, Item 9.01
D1 -1.3% · +5d +0.2%
2026-07-29Earnings
Earnings report
D1 -1.3% · +5d +0.2%

$VKTX — what investors on X are saying · SpikePanel

$VKTX (Viking Therapeutics, Inc.) — investor discussion on X

Five-factor rating: Sell (sector percentile 0.8%)

Recent discussion events

Most active credible voices on $VKTX

Recent headlines featuring $VKTX

$VKTX (Viking Therapeutics, Inc.) — investor discussion on X

Five-factor rating: Sell (sector percentile 0.8%)

Recent discussion events

Most active credible voices on $VKTX

Recent headlines featuring $VKTX

Viking Q3 Loss Widens, VK2735 Maintenance Data Met but Stock Fell

8-K: Item 2.02, Item 9.01

Earnings report

Rex Shares Launches Peptide ETF; VKTX Among Top 10 Holdings

VKTX Rebounds 2.88% to $28.53 After Offering

Viking Appoints VP of Market Access, Bolsters Commercialization

8-K: Item 1.01, Item 2.03, Item 9.01

8-K: Item 8.01, Item 9.01

Dimensional Fund Advisors Raises VKTX Stake by 18%

VKTX Faces Shareholder Probe, Q2 Earnings Loom

VKTX Reports Q2 Results, Phase 3 VK2735 Trials Fully Enrolled

8-K: Item 2.02, Item 9.01

Earnings report

Bull vs bear

Discussion

Viking Q3 Loss Widens, VK2735 Maintenance Data Met but Stock Fell

8-K: Item 2.02, Item 9.01

Earnings report

Rex Shares Launches Peptide ETF; VKTX Among Top 10 Holdings

VKTX Rebounds 2.88% to $28.53 After Offering

Viking Appoints VP of Market Access, Bolsters Commercialization

8-K: Item 1.01, Item 2.03, Item 9.01

8-K: Item 8.01, Item 9.01

Dimensional Fund Advisors Raises VKTX Stake by 18%

VKTX Faces Shareholder Probe, Q2 Earnings Loom

VKTX Reports Q2 Results, Phase 3 VK2735 Trials Fully Enrolled

8-K: Item 2.02, Item 9.01

Earnings report